Tuberculosis vaccine gets a shot at the coronavirus

| | May 15, 2020
original
Credit: Pascal Rossignol/Reuters
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

One of the oldest vaccines could protect us against our newest infectious disease, COVID-19. The vaccine has been given to babies to protect them against tuberculosis for almost a century, but has been shown to shield them from other infections too, prompting scientists to investigate whether it can protect against the coronavirus.

This Bacille Calmette-Guérin (BCG) vaccine, named after two French microbiologists, consists of a live weakened strain of Mycobacterium bovis, a cousin of M. tuberculosis, the bacterium that causes tuberculosis.

[R]esearchers decided to compare data from countries with and without mandatory BCG vaccination to see if immunization policies are linked to the number or severity of COVID-19 infections. A handful of preprint publications in the last two months noted that countries with an ongoing BCG vaccination program are experiencing lower death rates from COVID-19 than those without.

Related article:  Priming the body's immune system with personalized cancer vaccines

One study, for instance, found that mandatory BCG was associated with a significantly slower climb in both confirmed cases and deaths during the first 30-day period of an outbreak.

In the absence of clinical trial data, the World Health Organization does not recommend BCG for the prevention of COVID-19. There is concern that people might jump the gun and decide BCG is effective before the trial results come out.

Read the original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend